SAN FRANCISCO--(BUSINESS WIRE)--New clinical data from four Phase 2 clinical trials of the investigational hepatitis C protease inhibitor telaprevir (VX-950) to be presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco support a broad profile for telaprevir in the treatment of chronic genotype 1 hepatitis C virus infection. Telaprevir is being developed by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in collaboration with Tibotec.
